BioLineRx (BLRX) Tops Q3 EPS by 4c

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07).

The Company held $38.9 million in cash, cash equivalents and short-term bank deposits as of September 30, 2016.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c